Bio-Rad Laboratories Class A
478 hedge funds and large institutions have $9.85B invested in Bio-Rad Laboratories Class A in 2020 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 177 increasing their positions, 175 reducing their positions, and 52 closing their positions.
23% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 52
13% more capital invested
Capital invested by funds: $8.68B → $9.85B (+$1.17B)
2% more funds holding
Funds holding: 469 → 478 (+9)
1% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 175
0.22% less ownership
Funds ownership: 78.59% → 78.38% (-0.22%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
36% less call options, than puts
Call options by funds: $9.43M | Put options by funds: $14.8M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$298M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$81.6M |
| 3 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$29.7M |
| 4 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
+$28.8M |
| 5 |
Legal & General Group
London,
United Kingdom
|
+$26.1M |
Top Sellers
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$76.9M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$60M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$58.2M |
| 4 |
Goldman Sachs
New York
|
-$55.9M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$39.5M |
BIO Hedge Fund Activity: Q3 2020 in Review
478 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2020, worth a combined $9.85B — up 13% from $8.68B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new BIO positions and 52 closed out — a net gain of 12 holders — while 177 added to existing stakes and 175 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $298M. The largest seller was Assenagon Asset Management, cutting an estimated $76.9M.
- 478 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2020, up from 469 in Q2 2020.
- Funds reported $9.85B of Bio-Rad Laboratories Class A stock for Q3 2020, up 13% quarter-over-quarter.
- 64 funds opened new Bio-Rad Laboratories Class A positions in Q3 2020 and 52 closed out, a net change of +12 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q3 2020 was Fidelity Investments, an estimated $298M added.
- The largest Bio-Rad Laboratories Class A seller in Q3 2020 was Assenagon Asset Management, an estimated $76.9M sold.
Based on aggregated 13F filings for Q3 2020.